1. Home
  2. ABUS vs WEAV Comparison

ABUS vs WEAV Comparison

Compare ABUS & WEAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • WEAV
  • Stock Information
  • Founded
  • ABUS 2005
  • WEAV 2011
  • Country
  • ABUS United States
  • WEAV United States
  • Employees
  • ABUS N/A
  • WEAV N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • WEAV EDP Services
  • Sector
  • ABUS Health Care
  • WEAV Technology
  • Exchange
  • ABUS Nasdaq
  • WEAV Nasdaq
  • Market Cap
  • ABUS 711.2M
  • WEAV 600.1M
  • IPO Year
  • ABUS N/A
  • WEAV 2021
  • Fundamental
  • Price
  • ABUS $4.38
  • WEAV $6.65
  • Analyst Decision
  • ABUS Strong Buy
  • WEAV Strong Buy
  • Analyst Count
  • ABUS 2
  • WEAV 5
  • Target Price
  • ABUS $5.00
  • WEAV $15.10
  • AVG Volume (30 Days)
  • ABUS 1.4M
  • WEAV 1.0M
  • Earning Date
  • ABUS 11-05-2025
  • WEAV 10-29-2025
  • Dividend Yield
  • ABUS N/A
  • WEAV N/A
  • EPS Growth
  • ABUS N/A
  • WEAV N/A
  • EPS
  • ABUS N/A
  • WEAV N/A
  • Revenue
  • ABUS $15,416,000.00
  • WEAV $220,834,000.00
  • Revenue This Year
  • ABUS $138.02
  • WEAV $19.01
  • Revenue Next Year
  • ABUS N/A
  • WEAV $16.11
  • P/E Ratio
  • ABUS N/A
  • WEAV N/A
  • Revenue Growth
  • ABUS 53.23
  • WEAV 18.10
  • 52 Week Low
  • ABUS $2.71
  • WEAV $6.35
  • 52 Week High
  • ABUS $5.10
  • WEAV $17.63
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 54.52
  • WEAV 34.73
  • Support Level
  • ABUS $4.25
  • WEAV $6.35
  • Resistance Level
  • ABUS $4.66
  • WEAV $7.28
  • Average True Range (ATR)
  • ABUS 0.17
  • WEAV 0.29
  • MACD
  • ABUS -0.03
  • WEAV -0.11
  • Stochastic Oscillator
  • ABUS 41.67
  • WEAV 17.95

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

Share on Social Networks: